OOIR: Observatory of International Research

Papers

(The TQCC of JACC-Heart Failure is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	242
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	182
Reply	163
Editorial Board	128
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	108
Developing a System for Best Performance for Cardiac Transplantation	103
Predictors of Incident Heart Failure Diagnosis Setting	87
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	77
Full issue PDF	76
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	75
Opportunities for Change in Home Health Care in Heart Failure	73
Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure	70
Correction	68
Revisiting ICD Therapy for Primary Prevention	64
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	62
Wearable Remote Patient Monitoring Devices	60
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	59
Long-Term Effects of Sotatercept on Right Ventricular Function	58
Reply	58
Eating to Prevent Both Heart and Planetary Failure	58
Reply	56
Associations Between Urinary Metal Levels and Incident Heart Failure	56
Curing Ourselves of Toxic Positivity for Hospital-at-Home	54
Reply	54
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	52

Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	51
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	51
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	50
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	48
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	48
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	48
Challenges Addressing Prognosis in Advanced Heart Failure	47
Thank You for the Privilege	46
GDF-15 in Cardiovascular Disease	45
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	44
The Path Toward a More Equitable Transplant System	44
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	43
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	42
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients	42
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	41
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	40
Advanced Heart Failure in the Cardiac Intensive Care Unit	39
Heart Failure With Preserved Ejection Fraction	38
Reply	38
Full Issue PDF	37
STRONG-HF	37
Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation	36
Compensation Models in Heart Failure	36
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	35
NT-proBNP	35
Prognosis for Acute Myocarditis	34
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	34
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	33
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	33
Racial and Genetic Differences	33
A Woman's Work Is Never Done	33
Heart Failure in Women	32
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction	32
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	32
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	32
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	31
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	31
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	31
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	31
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	31
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	30
Body Composition and Survival in Patients With Heart Failure	30
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	29
Guideline Recommendations for Sudden Cardiac Death Prevention in Patients With Hypertrophic Cardiomyopathy	28
Facts and Fallacies of Body Composition Analysis in Heart Failure	28
Every Journey Needs a Guide	28
Upper Body Hypoxemia During ECMELLA	27
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	27
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	27
Reevaluating Growth Hormone Therapy in HFrEF	27

Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	27
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	27
Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure	26
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	26
Therapeutic Options in Ambulatory Advanced Heart Failure	26
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	25
Management of Heart Failure–Related Cardiogenic Shock	25
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	25
Understanding and Investigating Sex-Based Differences in Heart Transplantation	25
Reply	24
Diabetes Therapy With SGLT2i After Heart Transplant	24
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	23
SGLT2 Inhibitors and Serious Renal Events Among Patients With Heart Failure With Reduced Ejection Fraction	23
Smoking Cessation Reduces the Risk of Heart Failure	23
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease	22
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	22
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	22
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	22
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction	22
Obesity and Weight Loss Strategies for Patients With Heart Failure	22
Chloride in Heart Failure	22
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	22
Bounded Rationality and Clinical Guidance Documents for Heart Failure	21
From Better Models to Better Care	21
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	21
Walking the Line Between Failure and Remission	21
Redefining Pre–Heart Failure With Cardiac Biomarkers	21
Full issue PDF	21
To ‘Plant or Not to ‘Plant, That Is the Question	21
Jump Starting the Heart	21
Instructions for Authors	21
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	21
Critical Importance of Genetic Screening in Family Members	20
Isolating Noise From Signals in the Air	20
Tafamidis in Octogenarians	20
Beyond Coronary Atherosclerosis	19
Editorial Board	19
Treatment of Obesity in Heart Failure	19
To Infinity and Beyond	19
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	19
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	19
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	18
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes	18
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	18
Illuminating a Hidden Risk	18
Moving From Prompts to Praxis With Remote Monitoring	18
Full issue PDF	18
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	18
Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis	17
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	17
Expanded Definition of Worsening Heart Failure	17
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	17
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	17
Reply	16
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction	16
A Pragmatic Approach to Weaning Temporary Mechanical Circulatory Support	16
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of HFrEF	16
Istaroxime in HFpEF	16
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	16
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	16
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	16
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	16
Full Issue PDF	16
Correction	16
Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure	16
Setting the Diagnosis of Heart Failure	16
Physical Activity Trajectories Preceding Incident Heart Failure	16
Pressure From Within and Without in Heart Failure With Preserved Ejection Fraction	15
Depressive Symptoms and Incident Heart Failure Risk in the Southern Community Cohort Study	15
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	15
Articulating the JACC Journals’ Direction in Times of Global Change	15
Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies	15
Bereavement and Mortality in Heart Failure	15
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	15
Deactivation of Left Ventricular Assist Devices at the End of Life	15
Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance	15
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial	15
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	14
Low Serum Ferritin Might Predict Incident Heart Failure	14
Reply	14

The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	14
The Link Between Heart Failure and Neurodegeneration	14
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	14
Impact of Female Sex on Cardiogenic Shock Outcomes	14
Shedding Light on the Darkness of MYH7 Cardiomyopathies	14
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF	14
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	14
Correction	14
Reply	14
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	13
Targeting Inflammation in Heart Failure Prevention	13
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	13
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	13
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	13
The Enigma of Natriuretic Peptides	13
Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation	13
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction	13
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	13
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	12
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	12
Angiotensin–Neprilysin Inhibition and Left Ventricular Assist Device Therapy –Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsar	12
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	12
Full issue PDF	12
Redefining Boundaries in Heart Failure Care	12
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	12
Reducing Pediatric Heart Failure Readmissions	12
Aging in Heart Failure	12
Information for Authors	12
Correction	12
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	12
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	12
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure	12
Contemporary American and European Guidelines for Heart Failure Management	12
Missing the True Target in Advanced Heart Failure	12
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	12
Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	12
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	11
The HeartMate 3 Risk Score	11
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	11
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	11
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients	11
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	11
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	11
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	11
Pregnancy as a Sentinel Event	11
REPLY	11
Reflections on Early Rehabilitation in Acute Heart Failure	11
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	11
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	11
Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy	11
Coronary Artery Disease Is Still a Major Cause of Heart Failure	10
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure	10
Survival of the Fittest	10
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation	10
Officers Page	10
Renal Compression in Heart Failure	10
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	10
Can We Manage Presymptomatic TTR V142I Related Risk?	10
Measures to Improve Trial Enrollment	10
Pulse Pressure Augmentation During Exercise	10
Cardiac Magnetic Resonance Imaging vs Coronary Angiography as Primary Strategy in Newly Diagnosed Heart Failure	10
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction	10
But Is All Post-Transplant Lymphoproliferative Disorder Created Equal?	10
“Pharmacoequity” in Heart Failure Treatment	10
Migration Matters	9
Instructions for Authors	9
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF	9
Heart Failure and the Risk of Stroke	9
Barriers and Facilitators to Prescribing Guideline-Directed Medical Therapy for Heart Failure in the Indian Health Service	9
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)	9
Encouraging Data Encourage More Research on Optimal Medical Therapy for Patients With HFrEF	9
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction	9
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up	9
Targets for Success in Treatment of Patients Hospitalized for Heart Failure	9
Correction	9
Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment	9
Low Education Levels Linked to Increased Mortality Following Acute Heart Failure Hospitalization in Brazil	9
When the Data Changes, So Should We	9
Correction	9
Reply	9
Emerging Opportunities to Reduce Racial, Ethnic, and Gender Disparities in Advanced Heart Failure Care	9
Centrally Adjudicated Heart Failure Outcomes Are Needed in Clinical Trials	9
Moving the Goalposts to Improve Postdischarge Outcome for Patients With Cardiogenic Shock and Acute MI	9
Reply	9
Left Atrial-to-Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	9
Promoting Representation in Heart Failure Clinical Trials	9
Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure	9
Real-World Outcomes of SGLT2 Inhibitors in Very Elderly Patients With Heart Failure With Preserved Ejection Fraction	9
Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials	9
Prevalence and Prognostic Impact of Drug Use in Patients Hospitalized for Acute Heart Failure	8
Searching for Volume in All the Wrong Places	8
The Quagmire of Prognostication in Heart Failure	8
Linking Chronic Kidney Disease to Incident Heart Failure and Adverse Cardiac Remodeling Through the Plasma Proteome	8
Donor Diabetes Mellitus Status and Contemporary Outcomes After Cardiac Transplantation	8
Further Refining the In-Hospital Risk Assessment of Patients Presenting With Uncomplicated Acute Myocarditis	8